Quantcast

Latest Tacrolimus Stories

2011-01-06 06:00:00

HORSHOLM, Denmark, Jan. 6, 2011 /PRNewswire/ -- LifeCycle Pharma A/S (OMX: LCP) has announced positive top-line results from a Phase 2 clinical trial involving 58 patients comparing LCP-Tacro(TM) tablets administered once-daily versus Prograf® (tacrolimus) capsules (Astellas Pharma) administered twice-daily in de novo liver transplant patients for one year. These data confirm the previous positive experience with LCP-Tacro(TM) in stable kidney and liver transplant patients...

2011-01-06 06:00:00

HORSHOLM, Denmark, Jan. 6, 2011 /PRNewswire/ -- LifeCycle Pharma A/S (OMX: LCP) has as of November 23, 2010 completed its fully subscribed rights offering of 395,974,671 new shares at DKK 1.20 per share. The company raised gross proceeds of DKK 475 million (approximately $85 million) and net proceeds of approximately DKK 442 million (approximately $79 million). The funds will be used primarily to complete the Phase 3 program of LCP-Tacro. LCP-Tacro is a once-daily formulation of the...

2010-09-21 06:00:00

PITTSBURGH, Sept. 21 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Tacrolimus Capsules, 0.5 mg, 1 mg and 5 mg, the generic version of Astellas' Prograf® Capsules, a treatment to prevent rejection in people who have received certain organ transplants. Tacrolimus Capsules had U.S....

2010-08-24 06:00:00

SHENYANG, China, Aug. 24 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. ("3SBio") (Nasdaq: SSRX), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products and Isotechnika Pharma Inc. ("Isotechnika") (TSX: ISA), a biopharmaceutical company focused on the discovery and development of immune modulating therapeutics, today announced the signing of a development and commercialization agreement for voclosporin, a next...

2010-07-28 02:00:00

TARRYTOWN, N.Y. and TOKYO, July 28 /PRNewswire-FirstCall/ -- Regeneron Pharmaceuticals, Inc. ("Regeneron"; Nasdaq: REGN) and Astellas Pharma Inc. ("Astellas"; Headquarters: Tokyo, Japan; President & CEO: Masafumi Nogimori) announced today that Astellas has extended through 2023 the non-exclusive license agreement that allows Astellas to utilize Regeneron's VelocImmune® technology in its internal research programs to discover fully human monoclonal antibody product...

2010-07-02 07:00:00

MORRISTOWN, N.J., July 2 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), today announced that its subsidiary, Watson Laboratories, Inc., has received approval from the United States Food and Drug Administration on its Abbreviated New Drug Application (ANDA) for Tacrolimus 5 mg capsules, the generic equivalent to Astellas' Prograf® capsules. Watson intends to begin shipping the product immediately. Prograf ® 5 mg had total U.S....

2010-06-24 16:17:11

C2 monitoring and age are key factors Researchers at Erasmus MC University Medical Centre in The Netherlands found that cyclosporine treatment is a significant risk factor for the development of de novo cancer in liver transplant patients. Full details appear in the July issue of Liver Transplantation, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases (AASLD). The 1-year survival rate after liver transplantation has dramatically...

2010-03-04 10:12:00

DEERFIELD, Ill., March 4 /PRNewswire/ -- Takeda Pharmaceuticals North America, Inc. announced today that KAPIDEX(TM) (dexlansoprazole) will be marketed in the United States under the new product trade name DEXILANT(TM) (dexlansoprazole). The product is indicated for heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD), the healing of erosive esophagitis (EE) and the maintenance of healed EE. After receiving reports of dispensing errors between KAPIDEX...

2009-12-06 17:35:00

A drug that has become a mainstay of multiple myeloma treatment may outperform alternative therapies in re-establishing the immune system of patients who have received stem cell transplants from unrelated, partially matched donors, according to early clinical trial results to be presented by Dana-Farber Cancer Institute investigators at the American Society of Hematology's (ASH) annual meeting on Sunday, Dec. 6 (Abstract 48, Ernest N. Morial Convention Center, Room 243-245, 5:45 pm CT). The...

2009-11-10 00:30:00

CAMBRIDGE, Mass. and TOKYO, Nov. 10 /PRNewswire/ -- Ironwood Pharmaceuticals, Inc. and Astellas Pharma Inc. today announced that they have entered into an agreement providing Astellas exclusive rights to develop and commercialize the investigational compound linaclotide in Japan, Indonesia, Korea, the Philippines, Taiwan, and Thailand. Linaclotide is currently in Phase 3 clinical development in the United States for the treatment of irritable bowel syndrome with constipation (IBS-C) and...


Word of the Day
call-note
  • The call or cry of a bird or other animal to its mate or its young.
'Call-note' is newer than 'bird-call,' which originally referred to 'an instrument for imitating the note of birds' but now also refers to 'the song or cry of a bird.'
Related